《异动股》四环医药(00460.HK)急涨20%曾破顶再创近三年高 成交倍增
四环医药(00460.HK)继上月22日升至2.32元创近三年高位遇阻掉头回落股价始终守稳10天线,今天股价曾略破顶高见2.34元,现造2.28元,急涨20%,成交倍增至4.6亿股,涉资9.9亿元。
四环医药上周五公布,子公司轩竹生物自主研发用以治疗非酒精性脂肪肝炎(NASH)的XZP-5610项目药品,已於今年1月成功获得国家药品监督管理局批准开展临床试验。此外,上周四公布,集团注射液(克林澳)用於治疗急性缺血性脑卒中的新适应症已於去年底获得国家药监局批准,其是目前内地开展药品上市後临床研究以来唯一获批脑卒中治疗领域的药品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.